Pylera / Bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride
Restriction or avoidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Velcade / Bortezomib
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tracleer / Bosentan
Pharmacokinetics only · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Cycloset / Bromocriptine mesylate
Evidence gap · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Aplenzin / Bupropion hydrobromide
Dose or interval change · GFR/eGFR in mL/min as reported by the source
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
CABENUVA / cabotegravir rilpivirine / Cabotegravir/rilpivirine
Monitoring guidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Vocabria / Cabotegravir sodium
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Cometriq / Cabozantinib
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Cabometyx / Cabozantinib
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Atacand HCT / Candesartan cilexetil and hydrochlorothiazide
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Coreg / Carvedilol
Pharmacokinetics only · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Coreg CR / Carvedilol phosphate
Evidence gap · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Cancidas / Caspofungin acetate
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Suprax / Cefixime
Dose or interval change · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Teflaro / Ceftaroline fosamil
Dose or interval change · Cockcroft-Gault CrCl, mL/min
Local official-label summary. Read the exact source scope and cautions.
Fortaz / Ceftazidime / Tazicef
Dose or interval change · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Zevtera / ceftobiprole medocaril / Ceftobiprole medocaril sodium
Dose or interval change · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
Rocephin / Ceftriaxone
No adjustment within stated limits · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Celebrex / Celecoxib
Restriction or avoidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Vistide / Cidofovir
Restriction or avoidance · Serum creatinine, CrCl and urine protein
Local official-label summary. Read the exact source scope and cautions.
Plavix / Clopidogrel
Evidence gap · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Cotellic / Cobimetinib
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Welchol / Colesevelam hydrochloride
Evidence gap · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Seromycin / Cycloserine
Restriction or avoidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Sandimmune / Cyclosporine
Monitoring guidance · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Tafinlar / Dabrafenib
Pharmacokinetics only · Indexed GFR/eGFR, mL/min/1.73 m2
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Vizimpro / Dacomitinib
Evidence gap · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Fragmin / Dalteparin sodium
Monitoring guidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Dapzura RT / Daptomycin
Dose or interval change · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Darzalex / Daratumumab
Pharmacokinetics only · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Darzalex Faspro / Daratumumab/hyaluronidase-fihj
Pharmacokinetics only · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Enablex / Darifenacin
No adjustment within stated limits · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Prezcobix / Darunavir ethanolate and cobicistat
Restriction or avoidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Sprycel / Dasatinib
Pharmacokinetics only · Cockcroft-Gault CrCl, mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Xgeva / Denosumab
Monitoring guidance · Creatinine clearance (CrCl), mL/min
Local official-label summary. Read the exact source scope and cautions.
New source summary. Independent clinical review pending.
Austedo / Austedo XR / Deutetrabenazine
Evidence gap · Renal impairment categories as defined by the cited product label
Local official-label summary. Read the exact source scope and cautions.
Generic names and brands can lead to different formulations. Select the matching route and release type.
Renal tables retain their indication, units and dialysis assumptions. Do not combine doses and intervals from different protocols.
Read source qualifications, monitoring and interactions. A missing dose or absent result does not mean no adjustment.
See all 26 A-Z review statuses and remaining work | Current evidence additions and verification results
1215 product/formulation records and 1125 selected RX summaries are local. These are selected renal summaries, not complete prescribing monographs. Coverage and independent clinical review remain incomplete.
Review coverage details